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Some practical considerations in the design of multi-arm multi-
stage designs
Jerome Wulff, Nikolaos Demiris
Cambridge Clinical Trial Unit, Cambridge, United Kingdom
Trials 2019, 20(Suppl 1):P-2
Introduction: In the design of cancer clinical trials, one is often con-
cerned with a number of options in the event that several treatments
are of interest.
Methods: We explore in this work the distinct possibilities when four
treatments are available, one acting as control and three as poten-
tially efficacious alternatives. This design may be embedded within
the context of multi-arm multi-stage (MAMS) trials where one may
select a two- or three-stage design.
Potential Results: We explore the application of such designs, in-
cluding trade-offs between potential gains in the number of pa-
tients with additional stages contrasted with patients “lost” due
to practical considerations such as patients randomised in
dropped arms while waiting for interim analyses and inspection
by an Independent Data and Safety Committee. In addition, in
cancer studies one may focus on the primary end-point using a
time-to-event analysis or a binary outcome by looking at the
probability of (potentially progression-free) survival at a specific,
clinically meaningful, time point. The effect of such choices is ex-
tensively investigated.
Potential Relevance & Impact: We conclude with a discussion of the
available software for MAMS designs and their advantages and dis-
advantages in terms of accuracy.
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principle efficacy for designated targeted therapies in patient
subgroups identified through ctDNA screening (CRUK/15/010)
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Introduction: plasmaMATCH is a novel platform trial which assesses
the potential of circulating tumour DNA (ctDNA) screening to dir-
ect targeted therapies in advanced breast cancer (ABC) patients.
The trial recruited ahead of target and will report initial results
within 3years of first patient first visit demonstrating efficiency of
this design.
Methods: plasmaMATCH is an open-label, multi-centre phase IIa plat-
form trial, consisting of a ctDNA screening component and five paral-
lel treatment cohorts. Patients with an actionable mutation identified
at ctDNA screening are invited to enter Cohorts A-D to receive a tar-
geted treatment matched to the mutation identified (A: ESR1–ex-
tended-dose fulvestrant; B: HER2–neratinib+/-fulvestrant; C&D: AKT1
(or PTEN for Cohort D) –AZD5363+/-fulvestrant). Cohort E was added
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Introduction: Recruitment and retention of participants are the big-
gest challenges to successful delivery of trials. Many interventions
are used by trial teams to improve recruitment and retention; how-
ever, few have been rigorously evaluated. A Study Within A Trial
(SWAT) is a robust method to evaluate the effectiveness of interven-
tions for improving trial conduct. PROMoting THE USE of SWATs
(PROMETHEUS) aims to make embedding SWATs standard practice
across UK Clinical Trials Units (CTUs), by pump-priming and facilitat-
ing trial teams to start at least 25 SWATS of recruitment or retention.
Methods: We established a network of CTUs committed to starting
at least two SWATs of recruitment and/or retention interventions. We
identified promising recruitment and retention interventions from a
variety of sources including Cochrane systematic reviews and exist-
ing prioritisation exercises. We created a priority list of 7 recruitment
and 8 retention interventions, and developed template SWAT proto-
cols for testing them. We are inviting trial teams to apply for funding
of up to £5,000 to test one of our prioritised interventions or their
own. Successful applicants are given funding, methodological and
process support to embed and report the SWAT.
Results: 26 trial teams from 11 CTUs have been funded to undertake
30 SWATs of recruitment and retention strategies, exceeding our ini-
tial target of 25 SWATs ahead of schedule. Each recruitment and re-
tention intervention is being evaluated in up to five host trials, and
will be evaluated for its effectiveness in the context of individual tri-
als, as well as across different trial populations and contexts.
Discussion: The RCT community has shown that with enough finan-
cial and methodological support, many are willing to engage with
and implement SWATs to build rapidly the evidence base. This will
help to deliver trials in a timely manner, patients to receive better
treatments and funders to deliver on their objectives.
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The past 15 years have seen an exponential rise in published studies
in health research described as pilot or feasibility studies. Many of
these published studies are in preparation for larger randomised con-
trolled trials evaluating efficacy or effectiveness. The vast majority of
these studies are external pilot or feasibility studies conducted separ-
ately from the future larger randomised trial, andthe data they pro-
duce is used only to make decisions about whether and how to go
on to a larger study. However, there has also been a rise in the num-
ber of effectiveness or efficacy randomised controlled trials in which
the first part of the trial is a pilot phase used to test out the feasibil-
ity of trial processes such as recruitment and retention. These pilot
phases are usually called internal pilot studies.
A pilot or feasibility phase for trials of complex interventions is widely
recommended, for example by the UK MRC framework for the develop-
ment and evaluation of complex interventions and is expected by fun-
ders such as the UK NIHR. However, researchers still face the question
about whether and what sort of external pilot work is needed in rela-
tion to their own research area. In this talk, we will use some examples
of external pilot and feasibility studies to reflect on when external pilot
studies are particularly useful, and how to make judgements about
their objectives, design and conduct. The examples cover a range of
different health issues. We suggest that the usefulness of an external
pilot study in advance of a larger randomised controlled trial may be
best assessed on a case by case basis.
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– the barriers and enablers of trial recruiters: a qualitative
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Introduction: The Prioritising Recruitment in Randomised Trials Prior-
ity Setting Partnership Study (PRioRiTy PSP), identified and prioritised
unanswered questions around trial recruitment research. We utilised
qualitative research methods to answer Question 5 ‘What are the
barriers and enablers for trial recruiters?’ within the maternity care
setting.
The aim of this Qualitative Evidence Synthesis (QES) was to explore
the evidence on the recruiter’s experience and perceptions of recruit-
ing women during pregnancy & childbirth to trials. We were specific-
ally interested in exploring;
1)The recruiter’s perception and awareness of how their own role
(e.g. clinical or non-clinical) might influence recruitment.
2)The recruiter’s perception and experience of how the ‘type of trial’
(i.e. pharmaceutical, non-pharmaceutical,) might influence recruitment.
3)Explore the setting and environment in which recruitment is
undertaken.
Methods: Using SPIDER, a broad search of electronic databases
(Pubmed, CINAHL, Embase, PsycINFO) & grey literature (Scopus, for-
ward & backward citation searches) returned 13,401 citations. Ab-
stracts were independently screened by two reviewers, of these, 29
citations progressed to full text screening, resulting in 8 eligible pa-
pers. We designed a data extraction tool and critically appraised
using CASP checklist. A thematical approach to coding & synthesis
was undertaken, applying CERQual for confidence in review findings.
Timing of Potential Results: We have preliminary results and expect
the QES will be submitted for publication in December 2019.
Potential Relevance & Impact: The review will, for the first time, sys-
tematically synthesise existing research on factors associated with re-
cruitment to RCTs in maternity care from the recruiters perspective.
The findings will provide the basis and direction of an exploratory
qualitative study seeking to develop a statement of recommendation
(in collaboration with stakeholders) for successful recruitment of
women during pregnancy & childbirth to RCTs.
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Introduction; The Topic 2 randomised controlled trial (RCT) (NIHR-
HTA- 16/111/111) was set up to compare the effectiveness of thor-
acic epidural and paravertebral blockade in reducing chronic post-
thoractomy pain. Recruitment was anticipated to be difficult and the
QuinteT Recruitment Intervention (QRI) was integrated into the trial
design to optimise recruitment.
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